ESR1 and breast cancer: In addition, the number of ISET ERα positive identified CTCs in the setting of metastatic disease was surprisingly low compared to ISET ‘CTCs’ identified by just morphology in the early breast cancer subgroup, as it would be expected that CTC counts would be higher in more advanced disease.